NCT00532558终止3 期
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg vs Placebo in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension
Takeda0 个研究点目标入组 657 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 657
- 主要终点
- Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol
研究概览
简要总结
The purpose of the study is to determine the reduction of LDL-cholesterol level after treatment with 50 mg per day of lapaquistat acetate once daily (QD).
详细描述
This study is being conducted to determine the potential of lapaquistat acetate 50 mg per day to lower LDL-C levels compared with placebo. This study is also being conducted to further evaluate the safety and tolerability of lapaquistat acetate 50 mg over a period of 12 weeks. An optional, 48-week, open-label extension will follow the 12 week, double-blind treatment period to evaluate the long-term safety and tolerability of lapaquistat acetate 50 mg/day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females of childbearing potential who are sexually active must agree to use adequate contraception from screening throughout the duration of the study and for 30 days following the last dose.
- •Prior to Randomization, the participant has a mean low density lipoprotein cholesterol level greater than or equal to 130 mg/dL and less than or equal to 190 mg/dL for 2 consecutive samples.
- •Prior to Randomization, the subject has mean triglyceride level greater than or equal to 400 mg/dL for 2 consecutive samples.
- •Is willing and able to comply with the recommended, standardized diet.
排除标准
- •Has an nine aminotransferase or aspartate aminotransferase level greater than 1.5 times the upper limit of normal, identified during screening.
- •Has a serum creatinine greater than 133 mmol/L, identified during screening.
- •Has a creatine kinase greater than 3 times the upper limit of normal, identified during screening.
- •Has active liver disease or jaundice.
- •Has taken any fibrates within 42 days of Visit 1 or any lipid-lowering therapy for at least 30 days prior to Screening.
- •Has a previous history of cancer that has been in remission for less than 5 years prior to the first dose of study medication.
- •Has an endocrine disorder, such as Cushing's syndrome, hyperthyroidism, or inappropriately treated hypothyroidism affecting lipid metabolism.
- •Has a history of myocardial infarction, angina pectoris, unstable angina, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdominal aortic aneurysm, coronary angioplasty, coronary or peripheral arterial surgery, or multiple risk factors that confer a 10-year risk for cardiovascular heart disease greater than 20% based on Framingham risk scoring.
- •Has a positive hepatitis B surface antigen or hepatitis C virus antibody test, as determined by medical history.
- •Has a positive human immunodeficiency virus status or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
- •Has received any investigational medication 30 days prior to screening, (for drugs with a long half-life, within a period of less than 5 times the drug's half-life) or is participating in an investigational study.
- •Has received lapaquistat acetate in a previous clinical study or as a therapeutic agent.
- •Has a history or presence of clinically significant food allergy that would prevent adherence to the specialized diet.
- •Has a known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia).
- •Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain.
- •Has uncontrolled hypertension
- •Has had inflammatory bowel disease or any other malabsorption syndrome, or has had gastric bypass or any other surgical procedure for weight loss.
- •Has a history of drug abuse or a history of high alcohol intake within the previous 2 years.
- •Has type 1 or 2 diabetes mellitus.
研究组 & 干预措施
Lapaquistat Acetate 50 mg QD
Experimental
干预措施: Lapaquistat acetate (Drug)
Placebo QD
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol
时间窗: Week 12 or Final Visit
次要结局
- Change from Baseline in Total Cholesterol(Week 12 or Final Visit)
- Change from Baseline in High Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in Very Low Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in apolipoprotein A1 Timeframe: Week 12 or Final Visit(Week 12 or Final Visit)
- Change from Baseline in apolipoprotein B(Week 12 or Final Visit)
- Change from Baseline in non- High Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B(Week 12 or Final Visit)
- Change from Baseline in Triglycerides(Week 12 or Final Visit)
研究者
相似试验
已完成
3 期
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)Coronary DiseaseHypercholesterolemiaNCT00092625Organon and Co442
已完成
3 期
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)Coronary DiseaseHypercholesterolemiaNCT00092612Organon and Co372
已完成
3 期
An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)Coronary DiseaseHypercholesterolemiaNCT00092638Organon and Co450
终止
2 期
Efficacy of Lapaquistat Acetate in Subjects With HypercholesterolemiaHypercholesterolemiaNCT00865228Takeda224
已完成
3 期
A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)HypercholesterolemiaNCT00092651Organon and Co1,398